Oculis Holding (OCS)
NASDAQ:OCS
Want to see OCS full AI Analyst Report?
OCS Stock Chart & Stats
$27.46
$0.20(1.10%)
At close: 4:00 PM EST
$27.46
$0.20(1.10%)
Day’s Range― - ―
52-Week Range$16.00 - $30.68
Previous CloseN/A
Volume95.89K
Average Volume (3M)58.01K
Market Cap
$1.69B
Enterprise Value$1.24B
Total Cash (Recent Filing)$213.25M
Total Debt (Recent Filing)$2.32M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
May 07, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding57,169,476
10 Day Avg. Volume127,612
30 Day Avg. Volume58,014
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.46K
Enterprise Value/Gross Profit-85.97
Enterprise Value/Ebitda-12.99
Forecast
1Y Price Target
$50.75Price Target Upside84.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.74
Revenue Forecast (FY)$4.71M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsAnalyst highlights that pivotal Phase 3 readouts for OCS-01 topical eye drops could enable a New Drug Application filing if results are positive, potentially introducing a noninvasive treatment for diabetic macular edema.
Regulatory PathwayAnalyst notes that Breakthrough Therapy designation for privosegtor may accelerate development and attract intensive FDA guidance, supporting a faster regulatory review path for optic neuritis.
Targeted Therapy DevelopmentAnalyst emphasizes that a genotype-targeted registrational trial for licaminlimab represents a precision medicine strategy that could deliver differentiated benefit for a specific dry eye patient subgroup.
Bears Say
Financial PerformanceReported sizable annual net loss signals significant cash burn, raising concerns about the company's ability to sustain operations without additional funding.
Financing And Dilution RiskHigh cash burn relative to available cash increases the likelihood of a capital raise, which could dilute existing shareholders and weigh on the stock.
Liquidity Pressure On DevelopmentSustained cash outflows may force reprioritization of clinical programs or slow trial enrollment if additional capital is not secured, creating execution risk.
Oculis Holding News
OCS FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was $16.00 and its highest was $30.68 in the past 12 months.
What is Oculis Holding’s market cap?
Oculis Holding’s market cap is $1.69B.
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is May 07, 2026 which is today.
How were Oculis Holding’s earnings last quarter?
Currently, no data Available
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -0.51.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 57,169,476 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oculis Holding?
Currently, no hedge funds are holding shares in OCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.75 (84.81% Upside)
$50.75 (84.81% Upside)
Hedge Fund Trend
Increased
By 611.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.49%
12-Months-Change
Fundamentals
Return on Equity
-62.46%
Trailing 12-Months
Asset Growth
124.27%
Trailing 12-Months
Company Description
Oculis Holding
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
OCS Stock 12 Month Forecast
Average Price Target
$50.75
▲(84.81% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Spyre Therapeutics
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Upstream Bio, Inc.
―
Ownership Overview
―
Insiders
0.68% Mutual Funds
5.02% Other Institutional Investors
94.00% Public Companies and
Individual Investors